DRD2 and schizophrenia: This approach has not yet been exploited for antipsychotics, however a positive allosteric modulator (PAM) of dopamine D2 receptor, a peptidomimetic PAOPA, was proven efficient in attenuating symptoms of schizophrenia in animal models [16].